Case Comprehensive Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Case Comprehensive Cancer Center sits in the top decile of US sponsors by registered trial count (#90 of 15,742 sponsors by registered trial count).
Case Comprehensive Cancer Center: 407 sponsored US clinical trials, 55 recruiting.
Case Comprehensive Cancer Center sponsors 407 registered US clinical trials on ClinicalTrials.gov, 55 of them currently recruiting, and 257 completed. 13 of these trials are in Phase 3-4 (later-stage) and 203 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 18 trials.
Top-decile sponsor footprint
Case Comprehensive Cancer Center ranks in the top decile of sponsors by registered trial count (#90 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
257 of 325 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (79.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
407 total, page 6 of 9
Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
NCT01155583
Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer
NCT01158521
Alkaline Water in Reducing Skin Toxicity in Women With Breast Cancer Undergoing Radiation Therapy
NCT01487954
Vitamin D Supplementation on 15-Prostaglandin Dehydrogenase Expression in Barrett's Esophagus
NCT01465113
Radiosurgery Plus Bevacizumab in Glioblastoma
NCT01086345
Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma
NCT01045928
Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases
NCT00949247
Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
NCT01100528
Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer
NCT01126450
Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma
NCT00991991
Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT00941720
Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies
NCT01079832
Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases
NCT00910039
Study of Tumor Samples in Patients Undergoing Radiation Therapy or Surgery For Primary Melanoma of the Eye
NCT00952939
Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery
NCT00873002
Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy
NCT01083368
Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma
NCT01095094
Differences in Timely Cancer Diagnosis in African American and Caucasian Patients With Newly Diagnosed Colorectal Cancer
NCT00856115
Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)
NCT00947388
Quality of Life in Younger Leukemia and Lymphoma Survivors
NCT00956475
Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy
NCT00509093
Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer
NCT01118351
Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction
NCT00732745
Radiation Therapy in Treating Patients With Recurrent Breast Cancer
NCT00945061
Chemotherapeutic Agents in Brain/Breast
NCT00795678
Psychosocial Adjustment After Radiation Therapy in Patients With Cancer
NCT00905086
Exercise and Healthy Diet or Standard Care in Patients in Remission From Stage I or Stage II Endometrial Cancer
NCT00732173
Compliance to Vaginal Dilation Therapy in Patients Who Have Undergone Radiation Therapy For Stage IB, Stage IIA, Stage IIB, Stage IIIA, or Stage IIIB Cervical Cancer or Stage IA, Stage IB, Stage IIA, or Stage IIB Endometrial Cancer
NCT00735514
Fatigue Caused by Chemotherapy in Women Who Have Undergone Surgery for Breast Cancer and in Healthy Volunteers
NCT00909662
Laser Spectroscopy of Breast Tissue Through a Needle Device
NCT00918788
Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial
NCT00750009
Study of Natural Killer Cells in Bone Marrow and Blood Samples From Patients With and Without Hematologic Cancer
NCT00918658
Spectroscopy of Breast Tissue
NCT00918216
Older Patients With Newly Diagnosed Breast Cancer or Colon Cancer
NCT00740961
Study of Physical and Mental Health of Older Patients With Newly Diagnosed Cancer
NCT00769951
Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach
NCT00601705
Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer
NCT00608205
Study of Blood Samples From Older Patients at High Risk of Developing Prostate Cancer and From Healthy Male Participants
NCT00898274
Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00660816
Compliance to a Hormone Therapy Regimen in Breast Cancer
NCT00666822
Stereotactic Radiation Therapy in Treating Patients With Prostate Cancer
NCT00619515
Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck
NCT00720304
Menopausal Symptoms in Women With Breast Cancer or At High Risk of Breast Cancer Treated on Another Clinical Trial
NCT00666913
Sunitinib in Treating Patients With Locally Advanced Bladder Cancer
NCT00526656
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT01093586
Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors
NCT00892385
Disease Management Program or Usual Care in Patients With Stage III or Stage IV Lung Cancer, Pancreatic Cancer, Ovarian Cancer, or Colorectal Cancer, and Their Caregivers
NCT00684801
Partial Breast Radiation Therapy in Treating Women Undergoing Breast-Conserving Therapy for Early Stage Breast Cancer
NCT00527293
Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers
NCT00498979
Oral Cancer Screening Among Nursing Home Dentists in Ohio
NCT00526851
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 87 |
| Phase 2 | 116 |
| Phase 3 | 12 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Case Comprehensive Cancer Center pipeline
55 recruiting of 407 indexed (14% open); 257 completed (63%).
Phase mix: 13 late (III/IV) vs 203 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (18 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Case Comprehensive Cancer Center: open-pipeline peers nationwide
Peers matched on 407 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Case Comprehensive Cancer Center sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 407 trials (± recruiting share)
- University of Nebraska · 407 trials · 13% recruiting
- Takeda · 408 trials · 12% recruiting
- University of Kansas Medical Center · 408 trials · 23% recruiting
- St. Jude Children's Research Hospital · 410 trials · 22% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Beth Israel Deaconess Medical Center · 14% recruiting · 488 trials
- Wayne State University · 13% recruiting · 163 trials
- University of Michigan · 13% recruiting · 1,327 trials
- Albany Medical College · 13% recruiting · 52 trials
Related
What to do with this Case Comprehensive Cancer Center page
407 registered trials is a research-attention snapshot, not an endorsement of Case Comprehensive Cancer Center or any single study.
- 55 of Case Comprehensive Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Case Comprehensive Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Case Comprehensive Cancer Center pipeline card: 407 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.